BCG Vaccine Formulation Enhancing Lung T Cell Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TB vaccines, such as BCG, have variable efficacy against pulmonary tuberculosis and fail to induce high frequencies of lung resident T cells, which are critical for protection against TB, highlighting the need for formulations that enhance T cell responses and antigenic breadth.
Innovation Solution
A pharmaceutical formulation comprising modulating agents that increase expression of IFNγ, IL-2, TNF, and IL-17 in systemic and lung resident T cells, potentially administered via intravenous BCG vaccination to induce robust antigen-responsive CD4 and CD8 T cell responses across lung tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCG is administered by intradermal or intramuscular route, then vaccination coverage is achieved, but high frequencies of lung resident T cells are not induced
Solution Approach 1:
The patent changes the administration route parameter from intradermal/intramuscular to aerosol or intravenous, which fundamentally alters the delivery mechanism to directly target the lung tissue. This parameter change enables the vaccine to induce high frequencies of lung resident T cells while maintaining protection against TB
Solution Approach 2:
The patent introduces adjuvants as intermediary substances that enhance the immune response when BCG is administered via aerosol or intravenous route. These adjuvants act as mediators to boost the induction of lung resident T cells and broaden antigenic recognition, resolving the contradiction between protection efficacy and T cell induction capability
2Ease of manufacture
If conventional BCG vaccination is used, then administration is simple, but antigenic breadth is insufficient
Solution Approach 1:
The patent creates a composite vaccine formulation by combining BCG with specific adjuvants. This composite approach maintains the simplicity of BCG administration while the adjuvant component enhances antigenic breadth by stimulating broader T cell responses against diverse Mtb antigens, thus resolving the contradiction between ease of manufacture and adaptability
3Reliability
If high dose IV BCG is administered, then systemic and tissue resident T cells are induced, but mechanism understanding is limited
Solution Approach 1:
The patent employs multiple readout measures including cytokine production (IFN-γ, IL-2, TNF-α, IL-17), T cell frequency quantification, and antigen-specific response assessment to monitor and understand the mechanisms by which aerosol/IV BCG with adjuvants induces protective immunity. This feedback approach enables mechanistic understanding while achieving durable protection
Data Source
AI summary
Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFNγ, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFNγ, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.